News
November, 2010:
ApoLife Awarded a Grant from Qualified Tax Discovery Project Program
The Qualifying Tax Discovery Project (QTDP), by the IRS, awards credits or grants for projects that show significant potential to produce new cost-saving therapies, creates U.S. jobs and increases national competition for such therapies. ApoLife received a grant of $200,000 from the QTDP to support initial work on the company’s program to generate and develop a novel antibody –secretory IgA (sIgA) for mucosal therapy of C.difficile infections (CDI).
ApoLife has developed a Twin Cassette yeast platform technology for cost-effective production of antibodies for cancer and infectious disease therapies. ApoLife’s innovative approach will enable simultaneous expression of the 4 genes of sIgA in a single yeast cell to produce cost effective products. Clostridium difficile infections (CDI) are common in hospitals, adding over $1 billion annually to healthcare system costs. Because of high relapse rates and the emergence of antibiotic-resistant pathogens, there are unmet clinical needs in the management of CDI.
October, 2010:
ApoLife Winner of the MICHBIO Emerging Bioscience Showcase
ApoLife, a bioscience company that has developed a patented technology solution for the development of therapeutic antibodies, was the winner of the 4th annual Emerging Bioscience Companies Showcase competition held at the MichBio Expo.
MichBio is the statewide trade association for the bioscience industry and the Expo is the premier annual gathering of bioscience leaders and stakeholders. The Bioscience Showcase highlights up and coming bio companies who present their new technologies to an audience of venture capital and angel investors. Three judges evaluated the presentations and selected ApoLife as the 2010 Showcase winner.
September, 2010:
ApoLife Awarded Phase 1 NCI SBIR Contract for Cost Effective Process to Develop Biogeneric Cancer Antibodies
Michigan biotech company’s innovative approach to developing cost effective therapeutics for cancer and infectious diseases receives support from the National Institute of Health.
ApoLife was awarded a Phase I contract for $300,000 under NIH/NCI SBIR program: to accelerate development of cost effective products that benefit cancer patients. The peer-reviewed grant was awarded to support ApoLife’s project: Cost effective development of biogeneric Campath antibody for cancer from ApoLife’s proprietary yeast platform system. The successful completion of milestones in Phase I has the potential to result in a $2.5 million Phase II award for preclinical development of the Campath antibody for leukemia and its potential application to MS therapy.
Articles
ApoLife – Producing Effective, Affordable Therapeutics for Patients
March 12, 2011 ( Michigan Tech News )
http://www.mitechnews.com/articles.asp?Id=12877
ApoLife Hires 3 on 50 Percent Revenue Growth
February 8, 2011 ( model D )
http://www.modeldmedia.com/startupnews/apolifedetroit020811.aspx
Biosimilars Jumpstart Biotech in India
April 15, 2007 ( Gen. Eng. News, Vol.27, P.52)
http://www.genengnews.com/articles/chitem.aspx?aid=2099
ApoLife could sell for USD 50m, Abbott or Lilly preferred buyers, says President, January 17, 2007
Merger Market - Kimberly Ha in Singapore and Sasha Damouni in New York (link)
Company Update: ApoLife Touts Yeast-Based Expression System
Sep 15 2006 (Gen. Eng. News, Vol. 26, No. 16)
Company Cites Platform's Advantages from Discovery through Commercial Manufacturing
http://www.genengnews.com/articles/chitem.aspx?aid=1861
Development & Production of Antibodies
Aug 1 2006 (Gen. Eng. News, Vol. 26, No. 14)
Looking at the Needs and Challenges and Considering the Range of Possible Alternatives
http://www.genengnews.com/articles/chitem.aspx?aid=1832
Can India's IT Success be Replicated in Biotech?
Jun 15 2005 (Gen. Eng. News, Vol. 25, No. 12)
IP Regulations and Supportive Gov't Commitment for R&D Will Be the Key
http://www.genengnews.com/articles/chitem.aspx?aid=997
June 2, 2003 - Crain’s Detroit Business
Stroh offshoot brews up medical proteins using yeast
http://www.crainsdetroit.com/apps/pbcs.dll/article?AID=/20030602/SUB/306020905&SearchID=73243953430313
April 2, 1998 - The Detroit News Business Focus: Technology
Researcher seeks weapons against cancer. (link)
Protein Expression & Purification Volume 8, 1996, 447-455
Production, Purification & Characterization of Recombinant Human Hemoglobin Rainier Expressed in Saccharomyces cerevisiae.
Michigan Economic Development Corporation (MEDC) –
Life Science Company Profile- ApoLife, Inc,. (link)
Presentations
Antibodies and Beyond Antibodies:ApoLife President Dr. Motwani Chair:
Emerging Trends in Biotechnology:
IBC’s 4th Annual International Congress on Drug Discovery & Development of Innovative Therapeutics, India, October 10-12, 2007 in Hyderabad, India
ApoLife presented at CHI-PepTalk meeting in San Diego, Jan. 9-12, 2007
www.chi-peptalk.com
ApoLife presented at Bio Asia Meeting in Hyderabad, India, February 15-17, 2007
New Frontiers in Biotechnology-Novel technology for Antibody production
ApoLife presented at IBC BIOPHARM Asia Meeting, Singapore,December 12-14,2006
Developments in BioProcess Technology: New Strategies in Expression, Upstream and Downstream Processing
-A cost-effective system for screening and production of recombinant proteins using yeast (S.cerevisiae)
ApoLife presented at, IBC 16th International conference on Antibody Development & Production, SanDiego, CA February 27th – March 3rd, 2006
Screening and Production of Functional IgG, Antibody Fragments and Immunotoxins in Saccharomyces cerevisiae
http://www.bio.org/events/2006/poster/online/index.asp?lst=org
ApoLife presented at BIO 2005, Philadelphia,PA June 19-22
Antibody Production and Downstream Processing
High-level secretion of functional IgG, Fab and scFv antibody fragments and fusion proteins in Saccharomyces cerevisiae (link)
Awards
NIH-CAP Program 2005 – WWW.LARTA.ORG –
company selected in the NIH-CAP program
MEDC / MLSC Awards 2000 -2003 for ApoLife, Inc
Small Scale Production Services for Recombinant Protein
http://www.michigan.org/medc/cm/attach/F1BE7E0C-9CA5-4CAC-AA75-E3057475C686/2000_2003_MLSC%20Awards.pdf
SBIR Phase I & Phase II (NIH & NCI) - Fiscal year 1997-2001
http://grants2.nih.gov/grants/award/trends/congdist9701.txt |
